Metrics Contract Services, the U.S.-based contract pharmaceutical development and manufacturing division of Mayne Pharma, has signed a development and manufacturing agreement with ESSA Pharmaceuticals. Under the terms of the agreement, Metrics will provide formulation development, analytical services and manufacturing to support the client’s ongoing clinical development of an orally administered oncology drug.
 
“To support this project for ESSA Pharmaceuticals, Metrics will transfer their current tablet formulation and manufacturing process into our facility, perform development work to optimize the formulation, then scale up the process to be able to manufacture clinical supplies for ESSA’s clinical needs,” said John Ross, president of Metrics Contract Services.
 
The project, notes Ross, will enable Metrics to demonstrate not only its longtime expertise in supporting customers with development programs and its unique ability to support commercial production from the same campus, but also its leadership in producing novel oral solid dose therapies for oncology treatment.
 
“We are excited to partner with ESSA on a program that is ultimately intended to benefit cancer patients,” said Ross. “Our focus is keenly on novel drugs that make a difference.”